Search research articles
Contact Us
Filters
Showing results (131-140 of 149) with videos related to
Page
of 15
Sort By:
British Journal of Cancer
|
July 28, 2021
Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers
M A McAteer, J P B O'Connor, D M Koh, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
April 6, 2010
Radiotherapy research priorities for the UK
T S Maughan, T M Illidge, P Hoskin, et al.
The British Journal of Dermatology
|
September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study
R Dummer, A Guminksi, R Gutzmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D S Boss, G K Schwartz, M R Middleton, et al.
British Journal of Cancer
|
July 21, 2011
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
K J Harrington, L J Billingham, T B Brunner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 10, 2018
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
H-T Arkenau, A Italiano, G Mak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
P A Cassier, V Polivka, I Judson, et al.
British Journal of Anaesthesia
|
December 20, 2025
Identification of difficult airways in critical care units (ID-ACCT): a multicentre, survey-based prospective observational study
Thomas J McClelland, Adam J Boulton, Alicia A C Waite, et al.
Investigational New Drugs
|
April 4, 2016
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B Milojkovic Kerklaan, S Slater, M Flynn, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 149) with videos related to
Sort By:
Page
of 15
British Journal of Cancer
|
July 28, 2021
Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers
M A McAteer, J P B O'Connor, D M Koh, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
April 6, 2010
Radiotherapy research priorities for the UK
T S Maughan, T M Illidge, P Hoskin, et al.
The British Journal of Dermatology
|
September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study
R Dummer, A Guminksi, R Gutzmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D S Boss, G K Schwartz, M R Middleton, et al.
British Journal of Cancer
|
July 21, 2011
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
K J Harrington, L J Billingham, T B Brunner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 10, 2018
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
H-T Arkenau, A Italiano, G Mak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
P A Cassier, V Polivka, I Judson, et al.
British Journal of Anaesthesia
|
December 20, 2025
Identification of difficult airways in critical care units (ID-ACCT): a multicentre, survey-based prospective observational study
Thomas J McClelland, Adam J Boulton, Alicia A C Waite, et al.
Investigational New Drugs
|
April 4, 2016
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B Milojkovic Kerklaan, S Slater, M Flynn, et al.
Page
of 15